Athos Capital Ltd Purchases Shares of 2,500,000 Kenvue Inc. $KVUE

Athos Capital Ltd purchased a new stake in Kenvue Inc. (NYSE:KVUE) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 2,500,000 shares of the company’s stock, valued at approximately $40,575,000. Kenvue accounts for about 25.7% of Athos Capital Ltd’s portfolio, making the stock its 2nd largest position. Athos Capital Ltd owned about 0.13% of Kenvue as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Kenvue by 1.8% in the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after purchasing an additional 4,101,880 shares during the period. Geode Capital Management LLC boosted its position in shares of Kenvue by 1.2% during the second quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock worth $1,021,267,000 after buying an additional 604,953 shares during the period. American Century Companies Inc. grew its stake in shares of Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after buying an additional 6,781,640 shares in the last quarter. Independent Franchise Partners LLP grew its stake in shares of Kenvue by 233.4% in the second quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock valued at $654,388,000 after buying an additional 21,886,537 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Kenvue in the 2nd quarter valued at $537,418,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Kenvue

In other news, Director Jeffrey C. Smith bought 3,200,000 shares of Kenvue stock in a transaction that occurred on Friday, December 12th. The shares were purchased at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the acquisition, the director directly owned 27,307,632 shares in the company, valued at $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.68% of the company’s stock.

Kenvue Trading Up 0.9%

NYSE:KVUE opened at $18.41 on Friday. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17. The firm has a market cap of $35.29 billion, a PE ratio of 23.91, a price-to-earnings-growth ratio of 4.21 and a beta of 0.51. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The stock has a fifty day moving average price of $17.85 and a 200 day moving average price of $17.43.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.05. The company had revenue of $3.78 billion for the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.Kenvue’s revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.26 EPS. Sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were paid a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.5%. The ex-dividend date was Wednesday, February 11th. Kenvue’s dividend payout ratio is presently 107.79%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on KVUE shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Citigroup lifted their target price on Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. UBS Group boosted their price target on shares of Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Canaccord Genuity Group increased their price target on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. Finally, Barclays raised their price objective on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Friday. Three investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.